The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 443-460

  Blume, Karl G ^a   Krance, Robert A ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Compatibility of donor recipient pair; Conditions affecting treatment outcomes; Counseling patients seeking multiple opinions; Disease and remission status; Evaluation and counseling of candidates for hematopoietic cell transplantation; Patient oriented issues in hematopoietic cell transplantation; Psychosocial assessment; Second counseling meeting

Indexed keywords

EID: 84890763298     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch30     Document Type: Chapter

References (135)

1. Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidencebased guidelines. Ann Intern Med 1996; 125: 625-33.
2. Bach PB, Schrag D, Nierman DM et al. Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood 2001; 98: 3234-40.
3. Loberiza FR, Jr. Zhang MJ, Lee SJ et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005; 105: 2979-87.
4. Lee SJ, Fairclough D, Antin JH, Weeks JC. Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA 2001; 285: 1034-8.
5. Joffe S, Mello MM, Cook EF, Lee SJ. Advance care planning in patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 65-73.
6. Fielding AK, Richards SM, Chopra R et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ ECOG 2993 study. Blood 2007; 109: 944-50.
7. Harrison DT, Flournoy N, Ramberg R et al. Relapse following marrow transplantation for acute leukemia. Am J Hematol 1978; 5: 191-202.
8. Spruce WE, Forman SJ, Krance RA et al. Outcome of bone marrow transplantation in patients with extramedullary involvement of acute leukemia. Blut 1983; 48: 75-9.
9. Thompson CB, Sanders JE, Flournoy N, Buckner CD, Thomas ED. The risks of central nervous system relapse and leukoencephalopathy in patients receiving marrow transplants for acute leukemia. Blood 1986; 67: 195-9.
10. Cutler CS, Lee SJ, Greenberg P et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-85.
11. Chao NJ, Nademanee AP, Long GD et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 1991; 9: 1575-9.
12. Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 9-16.
13. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-71.
14. Aversa F, Tabilio A, Terenzi A et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-55.
15. Henslee-Downey PJ, Abhyankar SH, Parrish RS et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864-72.
16. Soiffer RJ, Mauch P, Fairclough D et al. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant 1997; 3: 11-17.
17. Aversa F, Terenzi A, Felicini R et al. Mismatched T cell-depleted hematopoietic stem cell transplantation for children with high-risk acute leukemia. Bone Marrow Transplant 1998; 22(Suppl 5): S29-32.
18. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-100.
19. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-93.
20. Ruggeri L, Mancusi A, Capanni M et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-40.
21. Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-13.
22. Speiser DE, Tiercy JM, Rufer N et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87: 4455-62.
23. Petersdorf EW, Hansen JA, Martin PJ et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001; 345: 1794-800.
24. Petersdorf EW, Kollman C, Hurley CK et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 2001; 98: 2922-9.
25. Drobyski WR, Klein J, Flomenberg N et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 2002; 99: 806-14.
26. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-8.
27. Weisdorf DJ, Anasetti C, Antin JH et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99: 1971-7.
28. Remberger M, Ringden O, Blau IW et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739-45.
29. Karnofsky DA, Abelmann WH, Craver LF. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634-56.
30. Sullivan KM, Siadak MF. Stem cell transplantation. St Louis: Mosby; 1997.
31. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-63.
32. Khouri IF, Keating M, Korbling M et al. Transplant- lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-24.
33. Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versuslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-9.
34. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-8.
35. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graftversus- tumor effects. Blood 2001; 97: 3390-400.
36. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-9.
37. Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reducedintensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255-8.
38. Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071-8.
39. Oehler VG, Gooley T, Snyder DS et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782-9.
40. Carpenter PA, Snyder DS, Flowers ME et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791-3.
41. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777-83.
42. Barlogie B, Tricot G, Rasmussen E et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 2006; 107: 2633-8.
43. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
44. Sorror ML, Maris MB, Storer B et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961-8.
45. Appelbaum F, Strauchen JA, Graw RG, Jr. et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976; 1: 58-62.
46. Cazin B, Gorin NC, Laporte JP et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061-9.
47. Trigg ME, Finlay JL, Bozdech M, Gilbert E. Fatal cardiac toxicity in bone marrow transplant patients receiving cytosine arabinoside, cyclophosphamide, and total body irradiation. Cancer 1987; 59: 38-42.
48. Hertenstein B, Stefanic M, Schmeiser T et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998-1004.
49. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-23.
50. Bearman SI, Petersen FB, Schor RA et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 1990; 5: 173-7.
51. Depledge MH, Barrett A, Powles RL. Lung function after bone marrow grafting. Int J Radiat Oncol Biol Phys 1983; 9: 145-51.
52. Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED. Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987; 107: 648-56.
53. Prince DS, Wingard JR, Saral R, Santos GW, Wise RA. Longitudinal changes in pulmonary function following bone marrow transplantation. Chest 1989; 96: 301-6.
54. Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest 1992; 101: 1257-64.
55. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989; 111: 368-76.
56. Nichols DG, Walker LK, Wingard JR et al. Predictors of acute respiratory failure after bone marrow transplantation in children. Crit Care Med 1994; 22: 1485-91.
57. Jain B, Floreani AA, Anderson JR et al. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. The University of Nebraska Medical Center Bone Marrow Transplantation Pulmonary Study Group. Bone Marrow Transplant 1996; 17: 561-8.
58. McDonald GB, Hinds MS, Fisher LD et al. Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-67.
59. Locasciulli A, Bacigalupo A, Alberti A et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 1989; 48: 68-72.
60. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822-9.
61. Deeg HJ, Seidel K, Bruemmer B, Pepe MS, Appelbaum FR. Impact of patient weight on nonrelapse mortality after marrow transplantation. Bone Marrow Transplant 1995; 15: 461-8.
62. Dickson TM, Kusnierz-Glaz CR, Blume KG et al. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 299-305.
63. Blume KG, Forman SJ, Nademanee AP et al. Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older. J Clin Oncol 1986; 4: 1489-92.
64. Klingemann HG, Storb R, Fefer A et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986; 67: 770-6.
65. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-6.
66. Soiffer RJ, Fairclough D, Robertson M et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 1997; 89: 3039-47.
67. Alyea EP, Kim HT, Ho V et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810-14.
68. Spyridonidis A, Bertz H, Ihorst G, Grullich C, Finke J. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies. Blood 2005; 105: 4147-8.
69. Lowsky R, Takahashi T, Liu YP et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353: 1321-31.
70. Hegenbart U, Niederwieser D, Sandmaier BM et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444-53.
71. Schmid C, Schleuning M, Schwerdtfeger R et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-9.
72. Sweetenham JW, Pearce R, Philip T et al. Highdose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party. Bone Marrow Transplant 1994; 14: 981-7.
73. Cahn JY, Labopin M, Mandelli F et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. Blood 1995; 85: 575-9.
74. Miller CB, Piantadosi S, Vogelsang GB et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 1996; 14: 1327-32.
75. Kusnierz-Glaz CR, Schlegel PG, Wong RM et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol 1997; 15: 18-25.
76. Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51-4.
77. Klingemann HG, Deeg HJ, Self S, Thomas ED, Storb R. Is race a risk factor for allogeneic marrow transplantation? Bone Marrow Transplant 1986; 1: 87-94.
78. Mielcarek M, Gooley T, Martin PJ et al. Effects of race on survival after stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 231-9.
79. Oh H, Loberiza FR, Jr. Zhang MJ et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005; 105: 1408-16.
80. Martino R, Parody R, Fukuda T et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-36.
81. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
82. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
83. Krishnan A, Molina A, Zaia J et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001; 98: 3857-9.
84. Junghanss C, Boeckh M, Carter RA et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-85.
85. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-63.
86. Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977; 296: 61-6.
87. Anasetti C, Doney KC, Storb R et al. Marrow transplantation for severe aplastic anemia. Longterm outcome in fifty "untransfused" patients. Ann Intern Med 1986; 104: 461-6.
88. Deeg HJ, Self S, Storb R et al. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood 1986; 68: 1363-8.
89. Ho WG, Champlin RE, Winston DJ, Feig SA, Gale RP. Bone marrow transplantation in patients with leukaemia previously transfused with blood products from family members. Br J Haematol 1987; 67: 67-70.
90. Brittenham GM. Iron and the pathophysiology of bone marrow transplantation. Bone Marrow Transplant 1997; 19: 116-18.
91. Armand P, Kim HT, Cutler CS et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-8.
92. McKay PJ, Murphy JA, Cameron S et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17: 63-6.
93. Angelucci E, Muretto P, Lucarelli G et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997; 90: 994-8.
94. Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant 1993; 11: 319-27.
95. Chang G, Antin JH, Orav EJ, Randall U, McGarigle C, Behr HM. Substance abuse and bone marrow transplant. Am J Drug Alcohol Abuse 1997; 23: 301-8.
96. Bishop MM, Rodrigue JR, Wingard JR. Mismanaging the gift of life: noncompliance in the context of adult stem cell transplantation. Bone Marrow Transplant 2002; 29: 875-80.
97. Henry MC, Tashjian DB, Breuer CK. Neuroblastoma update. Curr Opin Oncol 2005; 17: 19-23.
98. Hahn T, Wall D, Camitta B et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005; 11: 823-61.
99. Khanna G, Van Heest AE, Agel J et al. Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2007; 39: 331-4.
100. Knechtli CJ, Goulden NJ, Hancock JP et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998; 92: 4072-9.
101. Peters C, Charnas LR, Tan Y et al. Cerebral Xlinked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004; 104: 881-8.
102. Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer 1987; 60: 1651-6.
103. Lof CM, Forinder U, Winiarski J. Risk factors for lower health-related QoL after allogeneic stem cell transplantation in children. Pediatr Transplant 2007; 11: 145-51.
104. Artz AS, Pollyea DA, Kocherginsky M et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954-64.
105. Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol 1998; 16: 3796-802.
106. Leneveu H, Bremont F, Rubie H et al. Respiratory function in children undergoing bone marrow transplantation. Pediatr Pulmonol 1999; 28: 31-8.
107. Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322: 417-21.
108. Jensen PD. Evaluation of iron overload. Br J Haematol 2004; 124: 697-711.
109. Nanda K. Non-alcoholic steatohepatitis in children. Pediatr Transplant 2004; 8: 613-18.
110. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a "growing" problem? J Hepatol 2007; 46: 1133-42.
111. Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 1981; 99: 46-50.
112. McDonald GB. Review article: Management of hepatic disease following haematopoietic cell transplant. Aliment Pharmacol Ther 2006; 24: 441-52.
113. Moore BD 3rd. Neurocognitive outcomes in survivors of childhood cancer. J Pediatr Psychol 2005; 30: 51-63.
114. Phipps S, Dunavant M, Srivastava DK, Bowman L, Mulhern RK. Cognitive and academic functioning in survivors of pediatric bone marrow transplantation. J Clin Oncol 2000; 18: 1004-11.
115. Peters C, Balthazor M, Shapiro EG et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996; 87: 4894-902.
116. Fife BL, Huster GA, Cornetta KG, Kennedy VN, Akard LP, Broun ER. Longitudinal study of adaptation to the stress of bone marrow transplantation. J Clin Oncol 2000; 18: 1539-49.
117. Siston AK, List MA, Daugherty CK et al. Psychosocial adjustment of patients and caregivers prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 27: 1181-8.
118. Phipps S, Dunavant M, Lensing S, Rai SN. Patterns of distress in parents of children undergoing stem cell transplantation. Pediatr Blood Cancer 2004; 43: 267-74.
119. Hummelinck A, Pollock K. Parents' information needs about the treatment of their chronically ill child: a qualitative study. Patient Educ Couns 2006; 62: 228-34.
120. Dermatis H, Lesko LM. Psychological distress in parents consenting to child's bone marrow transplantation. Bone Marrow Transplant 1990; 6: 411-17.
121. DuHamel KN, Manne S, Nereo N et al. Cognitive processing among mothers of children undergoing bone marrow/stem cell transplantation. Psychosom Med 2004; 66: 92-103.
122. Manne S, DuHamel K, Nereo N et al. Predictors of PTSD in mothers of children undergoing bone marrow transplantation: the role of cognitive and social processes. J Pediatr Psychol 2002; 27: 607-17.
123. Simms S, Kazak AE, Golomb V, Goldwein J, Bunin N. Cognitive, behavioral, and social outcome in survivors of childhood stem cell transplantation. J Pediatr Hematol Oncol 2002; 24: 115-19.
124. Sanders JE. Endocrine complications of highdose therapy with stem cell transplantation. Pediatr Transplant 2004; 8(Suppl 5): 39-50.
125. Sanders JE, Guthrie KA, Hoffmeister PA, Woolfrey AE, Carpenter PA, Appelbaum FR. Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood 2005; 105: 1348-54.
126. Stein J, Dini G, Yaniv I. The hope and the reality of reduced intensity transplants in children with malignant diseases. Bone Marrow Transplant 2005; 35(Suppl 1): S39-43.
127. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005; 353: 64-73.
128. Cheng YC, Saliba RM, Rondon G et al. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica 2005; 90: 1725-6.
129. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
130. Ades L, Guardiola P, Socie G. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev 2002; 16: 135-46.
131. Deeg HJ, Socie G, Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386-92.
132. Shama WI. The experience and preparation of pediatric sibling bone marrow donors. Soc Work Health Care 1998; 27: 89-99.
133. Packman W. Psychosocial impact of pediatric BMT on siblings. Bone Marrow Transplant 1999; 24: 701-6.
134. Packman WL, Crittenden MR, Schaeffer E, Bongar B, Fischer JB, Cowan MJ. Psychosocial consequences of bone marrow transplantation in donor and nondonor siblings. J Dev Behav Pediatr 1997; 18: 244-53.
135. Jacobe SJ, Hassan A, Veys P, Mok Q. Outcome of children requiring admission to an intensive care unit after bone marrow transplantation. Crit Care Med 2003; 31: 1299-305.